ERRATA

Far1 and Fus3 Link the Mating Pheromone Signal Transduction Pathway to Three G_1-Phase Cdc28 Kinase Complexes

MIKE TYERS AND BRUCE FUTCHER

Banting and Best Department of Medical Research, University of Toronto, Toronto, Ontario, Canada M5G 1L6, and Cold Spring Harbor Laboratory, P.O. Box 100, Cold Spring Harbor, New York 11724

Volume 13, no. 9, p. 5662: In Fig. 3, lanes 7 to 9 were designated incorrectly. The correct version of Fig. 3 is shown below.



FIG. 3. Association of Far1 with Cln-Cdc28 kinase complexes. (A) Phosphorylation of Far1 in Cln immunoprecipitates is enhanced by α-factor. Cultures were grown in the absence or presence of 5 μM α-factor for 3 h at 23°C, and 12CA5 immunoprecipitates were analyzed for Cln-associated kinase activity. The *GAL1-CLN3* strain was induced with 2% galactose for 1 h prior to the addition of α-factor. The anti-Far1 and the anti-Cln3 immunoprecipitates had very weak, associated kinase activities; therefore, these lanes (5, 6, 10, and 11) were exposed about 10 times longer than the other lanes in the top panel. The α-factor used in this experiment was less pure than that used in other experiments, and the Cln-associated kinase activity was recovering by the end of the experiment. However, by morphological assays, the cells remained arrested at 3 h. A portion of each mixture for the kinase reaction shown in the top panel was denatured and reimmunoprecipitated with 12CA5 antibody to detect the Clns (panel labelled 12CA5 re-IP) and with affinity-purified anti-Far1 antibody (panel labelled α-Far1 re-IP). The +PEP lane is a control for which an excess of the peptide defining the epitope has blocked the 12CA5 antibody. (B) Association of Far1 with Cln1 and Cln2 is increased by α-factor. A portion of each immunoprecipitate used for panel A was analyzed by immunoblot with 12CA5 antibody (top panel) and with affinity purified anti-Far1 serum (bottom panel). This assay is less sensitive than the kinase assay used for panel A. The strains used were GT102 (*CLN2C*), GT100-23c (*CLN1C*), and BF410-3b (*GAL1-CLN3C*). IgG, immunoglobulin G; IP, immunoprecipitation.